Journal of Dermatological Treatment,
Journal Year:
2023,
Volume and Issue:
34(1)
Published: Sept. 12, 2023
Atopic
dermatitis
(AD),
a
chronic-relapsing
inflammatory
skin
disorder,
manifests
with
intense
itching
and
eczematous
lesions
impairing
quality
of
life.
A
heterogeneous
population,
regional
clinical
practices
for
treating
AD
warrant
the
development
guidelines
in
Qatar.
Therefore,
management
moderate-to-severe
Qatar
have
been
developed
discussed.
Experts,
including
dermatologists
immunologists,
used
Delphi
technique
developing
guidelines.
Consensus
was
defined
as
≥75%
agreement
or
disagreement.
is
highly
prevalent
primary
tertiary
dermatology
centers.
AD-associated
foot
eczema
psoriasiform
are
more
frequent
than
Europe
USA.
SCORing
Dermatitis
Index
quantifies
disease
severity
itch.
Dermatology
Life
Quality
assesses
Control
Tool
long-term
control.
Moderate-severe
benefits
from
new
topicals
like
Janus-kinase-inhibitors
PDE4-inhibitors
combined
phototherapy.
Currently
approved
systemic
agents
dupilumab,
baricitinib,
abrocitinib,
upadacitinib.
New
anti-IL-13
anti-IL-31
therapies
will
soon
be
available.
Patient
education,
allergy
testing,
comorbidity
consideration
critical
AD.
The
expert
panel
established
comprehensive
pragmatic
approach
to
managing
AD,
thereby
assisting
decision-making
healthcare
professionals
Inflammation,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 14, 2025
Atopic
dermatitis
(AD)
is
a
multifaceted
inflammatory
skin
condition
characterized
by
the
involvement
of
various
cell
types,
such
as
keratinocytes,
macrophages,
neutrophils,
and
mast
cells.
Research
indicates
that
flavonoids
possess
anti-inflammatory
properties
may
be
beneficial
in
management
AD.
However,
investigation
glycoside
forms
for
anti-AD
therapy
limited.
We
aimed
to
assess
ability
quercetin-3-O-glycosides
treating
AD-like
lesions
through
silico-,
cell-,
animal-based
platforms.
The
glycosylated
flavonols
quercitrin,
isoquercitrin,
rutin
were
used
this
study.
also
tried
understand
influence
glycone
type
on
bioactivity
delivery
glycosides.
glycosides
effectively
reduced
overexpression
proinflammatory
effectors
interleukin
(IL)-6,
chemokine
(C-X-C
motif)
ligand
(CXCL)1,
CXCL8,
regulated
upon
activation
normal
T
expressed
secreted
(RANTES),
thymus
activation-regulated
(TARC)
activated
keratinocytes.
This
reduction
could
due
inhibition
extracellular
signal-regulated
kinase
(ERK)
p38
phosphorylation.
Isoquercitrin
(but
not
quercitrin
rutin)
arrest
upregulated
IL-6
CCL5
macrophage
model.
significantly
prevented
histamine
release
from
RBL-2H3
absorption
examination
showed
greater
permeation
isoquercitrin
than
with
dual
sugar
moieties
smaller
molecular
volume
higher
lipophilicity.
deposition
was
enhanced
about
11-fold
stripped
delipidized
skins,
which
mimicked
AD
lesions.
vivo
dinitrochlorobenzene
(DNCB)-induced
mouse
model
demonstrated
less
erosion,
scaling,
epidermal
hyperplasia
after
topical
treatment.
concentration
cytokines/chemokines
lesion
decreased
isoquercitrin.
These
effects
similar
those
tacrolimus
ointment.
immunohistochemistry
(IHC)
displayed
hyperproliferation
immune
infiltration
results
indicated
quercetin
provide
an
efficient
safe
way
treat
inflammation.
Seminars in Cell and Developmental Biology,
Journal Year:
2023,
Volume and Issue:
154, P. 199 - 207
Published: April 27, 2023
Atopic
dermatitis
(AD),
also
known
as
atopic
eczema,
is
a
common
but
complex
chronic,
itchy
skin
condition
with
underlying
inflammation
of
the
skin.
This
ailment
prevalent
worldwide
and
affects
people
all
ages,
particularly
children
below
five
years
age.
The
itching
resulting
rashes
in
AD
patients
are
often
result
inflammatory
signals,
thus
necessitating
closer
look
at
inflammation-regulating
mechanisms
for
putative
relief,
care
therapy.
Several
chemical-
well
genetically-induced
animal
models
have
established
importance
targeting
pro-inflammatory
microenvironment.
Epigenetic
gaining
attention
towards
better
understanding
onset
progression
inflammation.
physiological
processes
implications
pathophysiology
AD,
such
as,
barrier
dysfunction
either
due
to
reduced
filaggrin
/
human
β‐defensins
or
altered
microbiome,
reprograming
Fc
receptors
overexpression
high
affinity
IgE
receptors,
elevated
eosinophil
numbers
IL-22
production
by
CD4
+
T
cells
epigenetic
that
include
differential
promoter
methylation
and/or
regulation
non-coding
RNAs.
Reversing
these
changes
has
been
verified
reduce
burden
through
secretion
cytokines
IL-6,
IL-4,
IL-13,
IL-17,
etc,
benefit
against
experimental
models.
A
thorough
remodeling
potential
opening
avenues
novel
diagnostic,
prognostic
therapeutic
options.
Advanced Healthcare Materials,
Journal Year:
2024,
Volume and Issue:
14(4)
Published: Nov. 15, 2024
Understanding
the
myofibroblast
microenvironment
is
critical
to
developing
therapies
for
fibrotic
diseases.
Here
development
of
a
novel
human
tendon-on-a-chip
(hToC)
reported
model
this
crosstalk
in
peritendinous
adhesions,
which
currently
lacks
biological
therapies.
The
hToC
facilitates
cellular
and
paracrine
interactions
between
vascular
component,
contains
endothelial
cells
monocytes,
tissue
hydrogel
component
that
houses
tendon
macrophages.
It
found
replicates
some
aspects
vivo
inflammatory
phenotypes
preclinical
clinical
samples,
including
activated
mTOR
signaling,
inflammation,
contraction
induced
by
activation,
cytokines
secretion,
transendothelial
migration
monocytes
hydrogel.
Transcriptional
analysis
demonstrates
significant
overlap
enriched
pathways
with
tenolysis
activation
signaling.
Rapamycin
suppresses
inflammation
phenotype
hToC,
provides
proof-of-concept
its
utility
as
an
vitro
tool
investigating
multicellular
fibrosis
testing
therapeutics
mitigate
it.
Dermatology and Therapy,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 9, 2025
Atopic
dermatitis
(AD)
is
a
chronic
inflammatory
skin
disease.
611,
humanized
monoclonal
antibody,
selectively
targets
the
interleukin
(IL)-4
receptor
alpha,
thereby
inhibiting
signaling
of
both
and
IL-13.
This
phase
2
study
aimed
to
evaluate
efficacy
safety
611
in
Chinese
adults
with
moderate-to-severe
AD.
randomized,
double-blind,
placebo-controlled
was
conducted
between
October
2022
September
2023.
Eligible
patients
AD
were
randomly
assigned
1:1:1
ratio
receive
at
dose
either
300
mg
(loading
600
mg)
every
weeks
(Group
A)
or
4
B),
placebo
for
16
weeks,
followed
by
an
8-week
follow-up
period.
The
primary
endpoint
proportion
achieving
least
75%
reduction
Eczema
Area
Severity
Index
(EASI-75)
score
week
16.
pharmacodynamics
also
assessed.
After
treatment,
60.0%
Group
A
48.8%
B
achieved
EASI-75,
significantly
higher
than
group
(15.6%,
p
<
0.01).
Additionally,
doses
improved
Investigator's
Global
Assessment
(IGA)
scores,
peak
pruritus
numerical
rating
scale
(NRS),
other
endpoints.
Patients
receiving
demonstrated
significant
reductions
serum
thymus
activation-regulated
chemokine
(TARC)
total
immunoglobulin
E
(IgE)
levels.
incidence
treatment-emergent
adverse
events
(TEAEs)
similar
across
all
dosage
groups.
most
common
611-related
TEAE
upper
respiratory
tract
infections.
No
new
concerns
identified.
high
favorable
profile
ClinicalTrials.gov,
NCT05544591.
Frontiers in Allergy,
Journal Year:
2025,
Volume and Issue:
6
Published: April 3, 2025
Allergic
Eczema
(AE)
is
a
chronic,
relapsing
skin
condition
that
significantly
affects
the
quality
of
life
AE
patients
and
their
caretakers.
Decades
scientific
clinical
research
has
helped
understand
highly
complex
underpinnings
presentation
wherein
multitude
variables,
including
conspicuous
variables
such
as
environmental
allergens,
immunological
triggers,
genetic
predisposition
individuals,
to
more
nuanced
socio-economic
status,
play
an
important
part.
Given
complexity
disease,
it
imperative
develop
biomarkers
enabling
early
reliable
identifications
help
in
active
management
thereby
minimizing
impact
burden
disease
on
patients.
In
this
mini
review,
we
provide
brief
overview
AE,
affected
demographics,
trigger
its
onset,
summarize
discovery
various
total
specific
serum
IgE
levels,
Th2
cytokine
filaggrin
(FLG)
mutations,
periostin
levels
skin,
etc.
have
been
developed
over
years
further
improve
state
monitoring
progression.
Lastly,
also
interventions
therapies,
topical
agents,
phototherapy,
biologics,
are
available
manage
AE-related
complications.
While
vastly
improved
standard
care
diagnosis
for
patients,
there
still
many
unmet
needs
developing
non-invasive,
effective,
predictors
which
can
usher
better
personalized
treatments
demographics.
Journal of Clinical Medicine,
Journal Year:
2025,
Volume and Issue:
14(9), P. 2953 - 2953
Published: April 24, 2025
Background:
Atopic
dermatitis
(AD)
is
a
chronic
pruritic
inflammatory
disease
affecting
children
and
adults.
Upadacitinib
abrocitinib
are
selective
Janus
kinase
1
inhibitors
approved
for
the
treatment
of
moderate-to-severe
AD.
Although
their
efficacy
safety
described
in
phase
3
clinical
trials,
real-world
data
limited.
Objectives:
We
aimed
to
evaluate
effectiveness
upadacitinib
real-life
adult
population
with
AD
throughout
an
extended
observation
period.
Methods:
This
retrospective
observational
study
was
conducted
by
analyzing
from
electronic
records
IRCCS
Humanitas
Research
Hospital
January
2023
December
2024.
Patients
were
administered
either
(15
or
30
mg)
(100
200
mg).
Effectiveness
evaluated
using
clinician-reported
scores
(Investigator
Global
Assessment
[IGA]
Eczema
Area
Severity
Index
[EASI])
patient-reported
outcomes
(peak
pruritus
numerical
rating
scale
[PP-NRS])
at
weeks
8,
16,
32
52.
Statistical
significance
set
probability
value
(p-value)
<
0.05.
Adverse
events
also
collected.
Results:
In
total,
129
patients
included
study,
84
them
reached
52
weeks.
At
week
52,
EASI
75,
90,
100
responses
88.9%,
70.8%,
54.2%
upadacitinib,
100%,
91.7%,
75%
abrocitinib.
An
IGA
score
equal
0
achieved
84.7%
treated
100%
those
receiving
A
four-point
reduction
baseline
PP-NRS
reported
86.1%
83.3%
after
one
year
follow-up.
Conclusions:
Our
showed
comparable
even
higher
terms
compared
phase-3
no
new
concerns,
supporting
Journal of Clinical Medicine,
Journal Year:
2025,
Volume and Issue:
14(9), P. 3015 - 3015
Published: April 27, 2025
Background/Objectives:
Atopic
dermatitis
(AD)
is
a
chronic
inflammatory
skin
disease
characterized
by
recurrent
rashes
and
itching,
which
seriously
affects
the
quality
of
life
patients
brings
heavy
economic
burden
to
society.
The
treat-to-target
(T2T)
strategy
was
proposed
guide
optimal
use
systemic
therapies
in
with
moderate
severe
AD,
patients'
adherence
emphasized
along
combined
evaluation
from
both
health
providers
patients.
While
effective
treatments
for
AD
are
available,
non-adherence
treatment
common
clinical
practice
due
unawareness
self-evaluation
lack
concern
about
specific
follow-up
time
points
clinics,
leads
failure
repeated
relapse
AD.
Methods:
This
project
consists
three
parts.
First,
an
artificial
intelligence
(AI)
model
diagnosis
severity
grading
based
on
deep
learning
will
be
trained.
Second,
AI
assistant
decision-making
system
(AIADMS)
form
app
developed.
Third,
we
design
prospective,
randomized
controlled
trial
test
hypothesis
that
AIADMS
implementation
T2T
could
help
control
progression
improve
outcomes.
Results:
A
total
232
participants
diagnosed
included
allocated
into
group
or
group.
In
group,
assisted
using
during
process
management
at
scheduled
points,
including
2
weeks,
4
8
12
6
months,
months
after
treatment.
diagnosis,
treatment,
carried
out
according
current
routine
face-to-face
basis.
primary
outcome
overall
efficiency
rate
treating
objectives
PP-NRS,
EASI,
SCORAD,
POEM,
DLQI
weeks
calculated
as
"Total
number
5
objectives/total
*100%".
Spss20.0
software
used
analyze
data
principle
intent
treat.
Trial
Registration:
protocol
registered
National
Institutes
Health
Clinical
Trials
Registry
registration
NCT06362629
11
April
2024.
Conclusions:
study
aims
integrating
advanced
technology,
patient
engagement,
clinician
oversight
through
achieve
goals
safe
long-term
control.
Clinical and Translational Allergy,
Journal Year:
2025,
Volume and Issue:
15(5)
Published: May 1, 2025
Abstract
Background
Targeting
the
interleukin‐4
receptor
alpha
(IL‐4Rα)
subunit
has
proven
clinical
efficacy
in
atopic
dermatitis
(AD).
Objective
This
study
assessed
peripheral
phenotype
and
function
of
T‐cells,
but
also
levels
total
sIgE
its
receptors
AD
patients
receiving
dupilumab.
Methods
were
clinically
(
n
=
75)
blood
samples
taken
25).
Multiparametric
flow
cytometry
was
performed
to
characterize
T‐cell
subsets
(before
treatment
6
months
later).
Total
specific
IgE
measured
by
ImmunoCap,
soluble
CD23
FcεR1
serum
ELISA,
eosinophils
differential
analysis.
Results
SCORing
Atopic
Dermatitis
scores
body
surface
area
involvement
decreased
upon
after
67%
77%
from
baseline.
At
T
cell
level,
we
observed
a
0.55‐fold
reduction
Th2‐cells
mean
27%
increase
regulatory
T‐cells
baseline,
accompanied
shifts
towards
Th1
Th17
phenotypes.
Furthermore,
circulating
CD4
+
CXCR5
TFH17
TFH17.1
positive
cells
(mean
40%
42%)
T‐cell‐specific
IL‐2
(+0.96‐fold)
IL‐10
(+1.96‐fold)
secretion
increased,
whereas
IL‐4
−55%)
IL‐17A
−27%)
reduced.
Eosinophil
counts
−22%),
−47%)
House
Dust
Mite
−40%)
decreased,
remained
unchanged.
Conclusions
The
cytokine
profiles
during
anti‐IL4‐Ra
suggest
that
targeting
this
pathway
promotes
systemic
shift
compartment
reducing
helper
type
2
complementary
responses.
sustainability
these
disease‐modifying
effects
requires
further
investigation.
Journal of Clinical Medicine,
Journal Year:
2023,
Volume and Issue:
12(20), P. 6575 - 6575
Published: Oct. 17, 2023
Efforts
have
been
made
to
identify
factors
influencing
clinical
response
in
patients
with
atopic
dermatitis
(AD)
treated
dupilumab.
A
retrospective
single-center
observational
study
was
carried
out
by
analyzing
data
from
492
aged
12
years
and
older
moderate-to-severe
AD.
The
aimed
baseline
demographic
that
could
predict
the
achievement
of
a
mild
level
disease,
i.e.,
an
Eczema
Area
Severity
Index
(EASI)
≤
7,
within
4
weeks
dupilumab
initiation.
Classic,
generalized
lichenoid
inflammatory
phenotypes
compared
nummular
eczema
phenotype
(OR
=
6.9,
95%
CI
2.04-23.48
OR
4.22,
1.22-14.66,
respectively)
EASI
24
between
24-29,
≥
29
3.1,
1.81-5.41
1.8,
1.05-3.07,
respectively),
were
found
be
predictive
early
dupilumab,
highlighting
importance
biological
treatment